Status:
UNKNOWN
Chinese TaTME Registry Collaborative
Lead Sponsor:
Beijing Friendship Hospital
Collaborating Sponsors:
Ruijin Hospital
Peking Union Medical College Hospital
Conditions:
Rectal Cancer
Eligibility:
All Genders
Brief Summary
Total mesorectal excision (TME) is the gold standard procedure for treating rectal cancer. However, in patients with obesity, prostate hypertrophy, low located tumor or/and pelvic stenosis, the tradit...
Eligibility Criteria
Inclusion
- malignant or benign neoplasms of the rectum
- the lower edge of the tumor from the anal margin less than 10cm according to MRI or rigid endoscopy
- tolerable to surgery
- be able to understand and willing to participate in this registry with signature
Exclusion
- patients requiring emergency surgery such as obstruction，perforation and bleeding
- tumor involving adjacent organs, anal sphincter, or levator ani muscle
- muti-focal colorectal cancer
- preoperative poor anal function, anal stenosis, anal injury, or fecal incontinence
- history of inflammatory bowel disease or familial adenomatous polyposis
- can not tolerate the surgery
- history of serious mental illness
- pregnancy or lactating women
- preoperative uncontrolled infection
- the researchers believe the patients should not enrolled in
Key Trial Info
Start Date :
November 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 15 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03416699
Start Date
November 15 2017
End Date
November 15 2021
Last Update
January 31 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Friendship Hospital
Beijing, China